Trial · NCT01606878
Results by group75
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 75
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Maximum Tolerated Dose (MTD) of Crizotinib | Part C (Crizotinib, Cyclophosphamide, Topotecan Hydrochloride) | 215 | mg/m^2 | ||
| Number of Patients With Dose Limiting Toxicity (DLT) | Part A Dose Level 1 | 2 | Participants | ||
| Number of Patients With Dose Limiting Toxicity (DLT) | Part A Dose Level 2 | 2 | Participants | ||
| Number of Patients With Dose Limiting Toxicity (DLT) | Part B Dose Level 1 | 0 | Participants | ||
| Number of Patients With Dose Limiting Toxicity (DLT) | Part B Dose Level 2 | 0 | Participants | ||
| Number of Patients With Dose Limiting Toxicity (DLT) | Part B Dose Level 3 | 2 | Participants | ||
| Number of Patients With Dose Limiting Toxicity (DLT) | Part C Dose Level 1 | 0 | Participants | ||
| Number of Patients With Dose Limiting Toxicity (DLT) | Part C Dose Level 2 | 1 | Participants | ||
| Number of Patients With Dose Limiting Toxicity (DLT) | Part C Dose Level 3 | 2 | Participants | ||
| Number of Patients With Dose Limiting Toxicity (DLT) | Part D Dose Level 1 | 3 | Participants | ||
| Number of Patients With Dose Limiting Toxicity (DLT) | Part D Dose Level 2 | 3 | Participants | ||
| Number of Patients With Dose Limiting Toxicity (DLT) | Part PK Dose Level 2 | 1 | Participants | ||
| Area Under the Concentration | Part A Dose Level 1 | 3792.5 | Full Range 1808.8 to 5520.3 | hr*ug/mL | |
| Area Under the Concentration | Part B Dose Level 1 | 1549.3 | Full Range 811.4 to 2544.3 | hr*ug/mL | |
| Area Under the Concentration | Part B Dose Level 2 | 4070.5 | Full Range 3588.0 to 10145.9 | hr*ug/mL | |
| Area Under the Concentration | Part C Dose Level 1 | 1612 | Full Range 1612.0 to 1612.0 | hr*ug/mL | |
| Area Under the Concentration | Part C Dose Level 2 | 3796.6 | Full Range 2976.0 to 7299.3 | hr*ug/mL | |
| Area Under the Concentration | Part C Dose Level 3 | 7462.8 | Full Range 7462.8 to 7462.8 | hr*ug/mL | |
| Area Under the Concentration | Part D Dose Level 2 | 3248 | Full Range 3109.9 to 3386.1 | hr*ug/mL | |
| Area Under the Concentration | Part PK Dose Level 2 | 8881.3 | Full Range 5701.6 to 12061.0 | hr*ug/mL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01606878/results